SURPASS-2: tirzepatide vs semaglutide in type 2 diabetes
The head-to-head trial that put the dual agonist against the leading GLP-1 drug.
Dual agonist vs GLP-1
Semaglutide was the most effective widely used GLP-1 receptor agonist when tirzepatide arrived. SURPASS-2 was a direct head-to-head test in type 2 diabetes — the cleanest way to ask whether adding GIP activity translates into better outcomes.
Who and how
Adults with type 2 diabetes on metformin were randomized to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg, all once weekly, for 40 weeks. Primary endpoint was change in A1c, with body weight a key secondary endpoint.
Tirzepatide came out ahead
All three tirzepatide doses reduced A1c more than semaglutide 1 mg, with reductions reaching roughly 2.0–2.3 percentage points at higher doses. Weight reductions were also greater, increasing with dose. Gastrointestinal side effects — nausea, diarrhea, vomiting — were the most common in both groups and broadly similar in nature.
A 1 mg comparison
An important nuance: SURPASS-2 compared against semaglutide 1 mg, the approved diabetes dose at the time; higher semaglutide doses have since been studied for weight. So the trial shows tirzepatide superior to that specific comparator, not a final word on every dose of every GLP-1 drug. See our mechanism comparison for nuance.
Caveats
This was a diabetes trial; obesity outcomes come from the SURMOUNT program. Results are averages, and the branded product was studied. Compounded tirzepatide is not FDA-approved.
The comparator caveat, in context
Fair interpretation of SURPASS-2 hinges on one detail: the comparator was semaglutide 1 mg, the approved diabetes dose at the time, not the higher 2.4 mg dose later used for obesity. So the trial robustly shows tirzepatide outperformed that specific comparator on A1c and weight, but it is not a head-to-head against every semaglutide dose or against semaglutide's obesity formulation. This is a common source of overstatement in popular summaries. The trial remains highly informative — it is a large, well-designed, direct comparison — but the honest framing is “superior to semaglutide 1 mg in type 2 diabetes,” not “superior to semaglutide in all settings.” Cross-trial obesity comparisons also tend to favor tirzepatide on average, yet those involve different populations and designs and should be read cautiously. Keeping these distinctions straight is part of evaluating any drug claim, and it is why we point readers toward the primary publications rather than headline numbers.
Primary sources
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
Is tirzepatide better than semaglutide?
In SURPASS-2, tirzepatide produced greater A1c and weight reductions than semaglutide 1 mg in type 2 diabetes. The comparison was against the 1 mg dose, so it isn't the final word on every dose.
What doses were compared in SURPASS-2?
Tirzepatide 5, 10 and 15 mg versus semaglutide 1 mg, all once weekly, over 40 weeks.
Were side effects different?
Both drugs most commonly caused gastrointestinal effects like nausea and diarrhea, broadly similar in type.